The treatment landscape for chronic inflammatory rheumatic diseases offers scope for individual treatment decisions

With the ongoing expansion of the therapeutic landscape, treatment management for chronic inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) is also changing. The diseases are often associated with physical and psychological limitations and remission is the primary treatment goal in order to improve the patient’s quality of life.^1-5 Individual treatment decisions play an important role here.⁶ At the annual congress of the Swiss Society of Rheumatology (SGR), treatments for RA, PsA and AS were discussed at an interactive symposium.